CBD for Pets: Safety, Dosage & the Science for Dogs and Cats

The pet CBD market is one of the fastest-growing segments of the entire CBD industry. A 2023 survey by the American Pet Products Association found that approximately 11% of US dog owners had given their pet CBD in the past year, and UK adoption rates are tracking similarly. The conditions driving this interest mirror those in human CBD use: chronic pain — particularly the osteoarthritis that affects an estimated 20% of dogs over age one and a much higher proportion of geriatric animals — anxiety (separation anxiety, noise phobia, and generalised anxiety are extremely common in companion animals), and seizure disorders in dogs and cats.

Dogs and cats have endocannabinoid systems broadly analogous to those of humans. CB1 receptors are expressed in the mammalian brain, and CB2 receptors in peripheral immune tissues, of dogs and cats in distributions similar to those in humans. The principal difference of pharmacological importance is that dogs appear to have a significantly higher density of CB1 receptors in the cerebellum than humans — potentially explaining why dogs are substantially more sensitive to THC toxicity than humans. This makes the distinction between CBD and THC products absolutely critical for pet use: any product with meaningful THC content is potentially dangerous or lethal for dogs.

The most frequently cited and methodologically rigorous study of CBD in veterinary medicine is the 2018 randomised, double-blind, placebo-controlled crossover trial by Stephanie McGrath, Joseph Wakshlag, and colleagues at Cornell University College of Veterinary Medicine, published in the Frontiers in Veterinary Science. The study evaluated CBD oil at 2 mg/kg twice daily versus placebo in 22 dogs with osteoarthritis-associated pain, using validated pain assessment tools (the Canine Brief Pain Inventory and the Hudson Activity Scale, both veterinary-validated instruments) over a four-week treatment period with a two-week washout between arms.

The results were clinically meaningful: 80% of dogs in the CBD arm showed significant improvement in pain scores as measured by the veterinarian-administered Canine Brief Pain Inventory, and mobility was significantly improved on the Hudson Activity Scale. Owners also reported improvement in activity levels in the CBD group. Crucially, no significant adverse effects were noted at the doses used, and all standard veterinary clinical parameters (bloodwork, urinalysis, physical examination) remained within normal limits.

The study was conducted using a hemp-derived CBD oil (5 mg/ml, zero THC confirmed by COA) in a MCT carrier. The 2 mg/kg twice daily protocol (totalling 4 mg/kg/day) provides a useful evidence-based dosing reference for dogs with osteoarthritis-associated pain specifically. The Cornell group has subsequently published additional studies expanding the veterinary CBD evidence base, including work on CBD for seizures in epileptic dogs (2019, finding 89% reduction in seizure frequency with CBD adjunct therapy) and pharmacokinetic characterisation of CBD in dogs and cats.

The Cornell 2018 study's dosing protocol of 2 mg/kg twice daily (4 mg/kg/day) for dogs with osteoarthritis pain is the best evidence-based reference point currently available. However, some integrative veterinary practitioners use a lower starting dose for general wellness or anxiety — typically 0.5–1 mg/kg twice daily — and titrate upward. The following weight-based reference is a practical guide:

• 5 kg dog (small breed, e.g. Chihuahua, Toy Poodle): Starting dose 2.5–5 mg per dose, twice daily. Pain/arthritis therapeutic dose: 10 mg twice daily.
• 10 kg dog (e.g. Cocker Spaniel, Westie): Starting dose 5–10 mg per dose. Therapeutic dose: 20 mg twice daily.
• 20 kg dog (e.g. Border Collie, Bulldog): Starting dose 10–20 mg per dose. Therapeutic dose: 40 mg twice daily.
• 30 kg dog (e.g. Labrador, German Shepherd): Starting dose 15–30 mg per dose. Therapeutic dose: 60 mg twice daily.
• 40+ kg dog (e.g. Great Dane, Saint Bernard): Starting dose 20–40 mg per dose. Therapeutic dose: 80 mg twice daily.

Always start at the lower end of the range and observe your dog for 7–10 days before increasing. Signs of excessive CBD dose in dogs include excessive sedation, loss of balance (ataxia), and GI symptoms. These effects are dose-dependent and resolve with dose reduction. If you observe any ataxia, reduce the dose immediately — this indicates the CBD is producing effects above your dog's optimal level.

Cats present unique pharmacological challenges that make dosing and product selection more complex than for dogs. Unlike dogs and humans, cats have a well-documented deficiency in glucuronidation — a key Phase II liver detoxification pathway. Many compounds that are efficiently conjugated and excreted in other mammals accumulate in cats, which is why cats are so sensitive to paracetamol (acetaminophen), aspirin, essential oils, and many other compounds that are well-tolerated by dogs and humans. Whether this affects CBD metabolism in cats is not definitively established, but it argues for particular caution in dosing.

The available pharmacokinetic data on CBD in cats is limited but suggests that CBD is metabolised somewhat differently and potentially more slowly than in dogs. A Cornell group pharmacokinetic study found that cats given CBD at 2 mg/kg showed oral bioavailability of approximately 19%, with a half-life of approximately 2–4 hours — broadly similar to dogs. The most commonly recommended starting dose for cats in integrative veterinary practice is 0.5–1 mg/kg once or twice daily, considerably lower on a per-kilogram basis than typical dog dosing. For a 4 kg cat, that would be 2–4 mg per dose.

Cats are also notoriously difficult to medicate. CBD oils in MCT carrier are typically accepted by cats when added to wet food — the fat content of the food itself improves absorption. Some cats dislike the taste of hemp-seed-oil based products; MCT carrier tends to be more palatable. CBD treats formulated specifically for cats are available, but dose precision is lower than with oil. Never give cats CBD products formulated for dogs without recalculating the dose — many dog products are much higher potency and could easily overdose a cat.

Anxiety in pets — particularly dogs — is one of the most common reasons owners reach for CBD. Canine separation anxiety, affecting an estimated 14–20% of the domestic dog population, produces destructive behaviour, vocalisation, house-soiling, and self-injurious behaviour when dogs are left alone. Noise phobia (thunderstorm and fireworks anxiety) causes acute fear responses that in severe cases are genuinely dangerous to the animal. Travel anxiety causes significant distress during what should be a manageable experience.

CBD's anxiolytic mechanisms — 5-HT1A agonism, ECS modulation, amygdala reactivity reduction — are directly applicable to canine anxiety given the conservation of these neural circuits across mammals. Anecdotally, pet owner reports of CBD's benefit for anxiety in dogs are among the most consistently positive in the entire pet CBD literature. Systematic evidence is beginning to emerge: a 2022 pilot study in dogs with noise aversion found that CBD-treated dogs showed significantly lower behavioural anxiety scores during a noise challenge compared to placebo, though the study was small.

For situational anxiety (fireworks, travel, vet visits), a larger single dose — approximately 4 mg/kg — given 30–60 minutes before the anxious event is a rational protocol. For chronic separation anxiety, a consistent twice-daily regimen at standard doses (2 mg/kg) over at least four weeks is recommended, combined with behavioural modification techniques (gradual desensitisation, departure cue neutralisation). CBD in this context should be part of a comprehensive management plan rather than a standalone intervention for severe separation anxiety.

The single non-negotiable requirement for any pet CBD product is verified zero THC. Dogs are approximately five times more sensitive to THC toxicity than humans, and cats are even more so. Cannabis intoxication in dogs — which presents as ataxia, hyperaesthesia (increased sensitivity to stimuli), mydriasis (dilated pupils), vocalisation, urinary incontinence, and in severe cases cardiovascular effects — is increasingly common as cannabis legalisation expands and more dogs access owners' cannabis products accidentally. Even legal, trace THC amounts in human CBD products (up to 1 mg per container) could present a risk to small dogs if large quantities are consumed; for dedicated pet products, the standard should be non-detectable THC on a batch-specific COA.

Pet-specific CBD products are formulated with appropriate concentration ranges for pets, use palatable carrier oils (salmon oil, hemp seed oil, MCT), and avoid ingredients that are toxic to dogs or cats — xylitol (found in some human CBD gummies) is highly toxic to dogs and must never be used. Human CBD gummies are not appropriate for pets for this reason. Look for products with ISO/IEC 17025 accredited third-party testing, clear dosage instructions by weight, and ideally veterinary advisory board involvement in formulation.

The veterinary profession's relationship with CBD has evolved considerably since the early years when vets were legally prohibited from recommending it in many jurisdictions. In the UK, the Royal College of Veterinary Surgeons (RCVS) Code of Professional Conduct requires vets to act in the animal's best interests and to base recommendations on current evidence. As the evidence base has grown, more vets are now willing to discuss CBD openly and to incorporate it into multimodal treatment plans for chronic pain, anxiety, and epilepsy.

UK vets cannot prescribe CBD as a medicine (no veterinary product licence exists for CBD in the UK), but they can discuss it as a supplement and advise on safety and dosing in the context of a clinical consultation. In the US, state-specific legislation has progressively expanded veterinarians' ability to discuss and recommend CBD — California's AB 2215 (2022) was among the first state laws explicitly allowing vets to recommend CBD to clients. The WSAVA (World Small Animal Veterinary Association) published a position statement in 2021 acknowledging the emerging evidence for CBD in veterinary medicine while emphasising the need for more rigorous clinical trials.

The practical advice from integrative veterinary practitioners consistently centres on product quality (verified THC-free, batch-tested), appropriate dosing by weight, and involving your vet in any CBD use for a pet with underlying health conditions or on prescription medications. CBD can interact with veterinary drugs through the same CYP450 mechanisms as in humans — phenobarbital and potassium bromide, commonly used for canine epilepsy, may have their blood levels altered by CBD co-administration, potentially requiring dose adjustment.

Assessing CBD efficacy in pets requires careful behavioural observation since animals cannot self-report. For osteoarthritis pain, look for: improved mobility and willingness to climb stairs or jump; reduced stiffness after rest (the classic post-nap shuffle in arthritic dogs often noticeably improves); increased activity level and engagement with play; and reduced pain-related vocalisation or guarding of affected joints. Keeping a brief video diary of your dog's gait before and after two to four weeks of CBD supplementation can provide striking objective evidence of improvement.

For anxiety, assess: reduction in anxiety-specific behaviours (panting, pacing, destructive behaviour, house soiling in separation anxiety; trembling, hiding, escape attempts in noise phobia); improved recovery time after an anxiety trigger; and reduced pre-event hyperarousal. For seizure monitoring in epileptic dogs, accurate seizure logs are essential — note date, time, duration, and severity of each seizure to provide objective data for your vet and to detect any genuine reduction in frequency or severity.